Tivoxavir marboxil

Tivoxavir marboxil
Clinical data
Other namesTRX-100, AV5124, viroksavir, viroxavir
Identifiers
  • [(3R)-2-[(10S)-6,7-difluoro-5,10-dihydrothieno[3,2-c][2]benzothiepin-10-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC25H21F2N3O7S2
Molar mass577.57 g·mol−1
3D model (JSmol)
  • COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=C4SC=C6)C(=C(C=C5)F)F
  • InChI=InChI=1S/C25H21F2N3O7S2/c1-34-25(33)37-12-36-22-16(31)4-6-29-21(22)24(32)28-7-8-35-10-18(28)30(29)20-13-2-3-15(26)19(27)14(13)11-39-17-5-9-38-23(17)20/h2-6,9,18,20H,7-8,10-12H2,1H3/t18-,20+/m1/s1
  • Key:JFAAVTYPCCKWCW-QUCCMNQESA-N

Tivoxavir marboxil is an investigational new drug that is being evaluated by Traws Pharma, Inc. for the treatment of influenza. It is a cap-dependent endonuclease inhibitor.[1][2]

Chemistry

Tivoxavir marboxil the prodrug form of tivoxavir. The carbonate containing sidechain (marboxil) is cleaved enzymatically to yield the active form of the drug tivoxavir.[3]

References

  1. ↑ "Tivoxavir marboxil - Traws Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Karapetian RN, et al. (March 2021). "Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir". The Journal of Antimicrobial Chemotherapy. 76 (4): 1010–1018. doi:10.1093/jac/dkaa524. PMC 7953317. PMID 33367751.
  3. ↑ Timmins P (3 July 2025). "Industry update: the latest developments in the field of therapeutic delivery, March 2025". Therapeutic Delivery. 16 (7): 607–616. doi:10.1080/20415990.2025.2511471.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.